Takeda Pharmaceutical Company Limited

The Rockefeller University

Moriteru Asano

Hiroshi Banno

Takaharu Hirayama

Hironobu Maezaki

Yasuhiro Hirata

Ryo Mizojiri

Koji Ono

Masahiro Ito

Daisuke Tomita

Toshio Tanaka

Shinichi Imamura

Hidekazu Tokuhara

Yasuyoshi Arikawa

Terufumi Takagi

Yusuke Sasaki

Masanori Okaniwa

Yasuhiro Imaeda

Nobuki Sakauchi

Yusuke Tominari

Michiko Tawada

Noriyuki Nii

Nobuo Cho

Douglas Robert Cary

Akinori Toita

Naoki Iwamura

Hironori Kokubo

Jun Fujimoto

Nao Morishita

Masato Yoshida

Tomohiro Okawa

Hideki Furukawa

Yuta Tanaka

Michael Andrew Foley

Krista E Gipson

Kazuyoshi Aso

Tarun M Kapoor

Yoshiyuki Fukase

Yuichiro Amano

Yayoi Yoshitomi

Mayumi Imai

Shuntarou Tsuchiya

Yashuhiro Hirata

Sachie Takashima

Shuntaro Tsuchiya

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Compounds of formula: are useful as antitumor agents. In these compounds, Ris (a) (C-C) hydrocarbyl, (C-C)halohydrocarbyl, (C-C)hydroxyalkyl, or or Ris (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Pyrazoloquinazolinone antitumor agents

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

Bicyclic compound

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Monocyclic compound

Growing community of inventors

Tokushima, Japan

Moriteru Asano